Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Avadel Pharmaceuticals (AVDL)
NASDAQ:AVDL
Avadel Pharmaceuticals (AVDL) Stock Price & Analysis
619 Followers
AVDL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.50 - $19.09
Previous Close$15.49
Volume573.40K
Average Volume (3M)1.29M
Market Cap
$1.49B
Enterprise Value$1.39B
Total Cash (Recent Filing)$105.11M
Total Debt (Recent Filing)$2.62M
Price to Earnings (P/E)-8.4
Beta0.84
Next Earnings
Aug 07, 2024EPS Estimate
-$0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.84
Shares Outstanding96,118,523
10 Day Avg. Volume1,549,047
30 Day Avg. Volume1,290,564
Standard Deviation0.27
R-Squared0.10
Alpha0.06
Financial Highlights & Ratios
Price to Book (P/B)21.01
Price to Sales (P/S)53.24
Price to Cash Flow (P/CF)-13.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue49.58
Enterprise Value/Gross Profit51.13
Enterprise Value/Ebitda-9.47
Forecast
1Y Price Target
$24.29Price Target Upside56.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Avadel Pharmaceuticals News
PremiumPre-Earnings
Is AVDL a Buy, Before Earnings?
PremiumCompany Announcements
Avadel Pharmaceuticals Shifts to Nasdaq, Ends ADR Program
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAnalyst raises revenue estimates for the company, signaling confidence in its financial growth and market potential.
Market PenetrationWith a high percentage of top prescribers adopting Lumryz and improved payer coverage, the drug's market penetration is on a strong upward trajectory.
Regulatory ApprovalThe approval of Lumryz under the orphan drug act demonstrates its clinical superiority, increasing its competitive advantage in the market.
Bears Say
Financial PerformanceSG&A well above consensus causing a material bottom-line miss, as analysts failed to model 1Q24 expense for litigation vs. Jazz.
Legal IssuesJazz Pharmaceuticals is suing the FDA claiming the approval of Avadel Pharmaceutical's Lumryz is inconsistent with the orphan drug act.
Legal UncertaintyA final ruling from Judge Williams on patent infringement is still pending, which introduces uncertainty regarding future royalty payments.
---
Ownership Overview
14.52% Insiders
5.20% Mutual Funds
1.55% Other Institutional Investors
78.74% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AVDL FAQ
What was Avadel Pharmaceuticals’s price range in the past 12 months?
Avadel Pharmaceuticals lowest stock price was $9.50 and its highest was $19.09 in the past 12 months.
What is Avadel Pharmaceuticals’s market cap?
Currently, no data Available
When is Avadel Pharmaceuticals’s upcoming earnings report date?
Avadel Pharmaceuticals’s upcoming earnings report date is Aug 07, 2024 which is in 79 days.
How were Avadel Pharmaceuticals’s earnings last quarter?
Avadel Pharmaceuticals released its earnings results on May 08, 2024. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.232 by -$0.068.
Is Avadel Pharmaceuticals overvalued?
According to Wall Street analysts Avadel Pharmaceuticals’s price is currently Undervalued.
Does Avadel Pharmaceuticals pay dividends?
Avadel Pharmaceuticals does not currently pay dividends.
What is Avadel Pharmaceuticals’s EPS estimate?
Avadel Pharmaceuticals’s EPS estimate is -$0.18.
How many shares outstanding does Avadel Pharmaceuticals have?
Avadel Pharmaceuticals has 96,118,520 shares outstanding.
What happened to Avadel Pharmaceuticals’s price movement after its last earnings report?
Avadel Pharmaceuticals reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.232. Following the earnings report the stock price went down -10.616%.
Which hedge fund is a major shareholder of Avadel Pharmaceuticals?
Among the largest hedge funds holding Avadel Pharmaceuticals’s share is Woodline Partners LP. It holds Avadel Pharmaceuticals’s shares valued at 25M.
---
Avadel Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.29 (56.81% Upside)
$24.29 (56.81% Upside)
Blogger Sentiment
Bullish
AVDL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 79.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 1.2%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.59%
12-Months-Change
Fundamentals
Return on Equity
-779.92%
Trailing 12-Months
Asset Growth
19.30%
Trailing 12-Months
Company Description
Avadel Pharmaceuticals
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. It offers Bloxiverz, Vazculep, and Akovaz. The company was founded on December 1, 2015 and is headquartered in Dublin, Ireland.
---
AVDL Stock 12 Month Forecast
Average Price Target
$24.29
▲(56.81% Upside)
Technical Analysis
Best Analysts Covering AVDL
1 Year
1 Year Success Rate
17/24 ratings generated profit
1 Year Average Return
+68.94%
reiterated a buy rating last month
Copying Ami Fadia's trades and holding each position for 1 Year would result in 70.83% of your transactions generating a profit, with an average return of +68.94% per trade.
---